Author: Kelkar, Amar H ; Fragner, Michael ; Roberts, Jonathan C ; Morell, Jason ; Hobson, Jared ; Tarantino, Michael D ; Rajasekhar, Anita ; Imbo, Bailey

Background and objective Acquired hemophilia A (AHA) is an uncommon autoimmune bleeding disorder caused by the formation of neutralizing antibodies against endogenous factor VIII (FVIII). Delays between the onset of symptoms and the correct diagnosis of the condition lead to poor outcomes and a higher mortality rate. In this study, we aimed to analyze the impact of delays in diagnosis on AHA patients. Methods We conducted a retrospective study at a single hospital system between March 1, 2010, and January 17, 2017, which included six patients meeting the criteria for AHA diagnosis. Results Initial analysis revealed a median age of 79.5 years and a median time to diagnosis from the onset of bleeding of 14 days. Among the six patients, three had cancer (bladder, renal, and prostate) and three had unknown etiologies. One of the patients died prior to the initiation of a bypassing agent. The remaining five patients received recombinant FVIIa (NovoSeven®, Novo Nordisk, Bagsværd, Denmark), and two of those five required a second-line bypassing agent, recombinant porcine sequence FVIII (Obizur®, Takeda Pharmaceutical, Tokyo, Japan) for refractory bleeding. All five patients achieved hemostasis; however, three died within a year, and none of the patients survived for five years. Four of these five patients died directly from bleeding complications. Conclusions Based on our study findings and review of the literature, we propose an algorithm to potentially aid in the early diagnosis and treatment of AHA in emergency and non-specialized settings.

01 Jan 2021·Bioresource TechnologyQ1 · ENGINEERING & TECHNOLOGY

Efficient simultaneous utilization of glucose and xylose from corn straw by Sphingomonas sanxanigenens NX02 to produce microbial exopolysaccharide

Q1 · ENGINEERING & TECHNOLOGY

Article

Author: Li, Guoqiang ; Wu, Mengmeng ; Shi, Zhuangzhuang ; Shen, Yaqi ; Zhao, Xin ; Ma, Ting

Lignocellulosic biomass is a cheap and abundant carbon source in the microbial manufacturing industry. The native co-utilization of glucose and xylose from corn straw total hydrolysate (CSTH) by Sphingomonas sanxanigenens NX02 to produce exopolysaccharide Sanxan was investigated. Batch fermentation demonstrated that, compared to single sugar fermentation, co-substrate of glucose and xylose accelerated cell growth and Sanxan production in the initial 24 h with the same consumption rate. Additionally, NX02 converted CSTH into Sanxan with a yield of 13.10 ± 0.35 g/Kg, which is slightly higher than that of glucose fermentation. Coexistence of three xylose metabolic pathways (Xylose isomerase, Weimberg, and Dahms pathway), incomplete phosphoenolpyruvate-dependent phosphotransferase system, and reinforced fructose metabolism were recognized as the co-utilization mechanism through comparative transcriptome analysis. Therefore, strain NX02 has a prospect of becoming an attractive platform organism to produce polysaccharides and other bio-based products derived from agricultural waste hydrolysate rich in both glucose and xylose.

01 Jun 2018·Carbohydrate PolymersQ1 · CHEMISTRY

Enhancement of transparent hydrogel sanxan production in Sphingomonas sanxanigenens NX02 via rational and random gene manipulation

Q1 · CHEMISTRY

Article

Author: Tian, Xuefeng ; Wu, Mengmeng ; Li, Guoqiang ; Shen, Yaqi ; Shi, Zhong ; Wei, Weiying ; Dai, Xiaohui ; Qu, Jianmei ; Ma, Ting

Polymer sanxan is a novel microbial polysaccharide produced by Sphingomonas sanxanigenens NX02, which can produce poly-3-hydroxybutyrate (PHB) simultaneously. A strategy of combining rational and random gene manipulation was investigated to improve the yield of sanxan. Several crucial PHB biosynthesis genes were deleted through homologous recombination, then the PHB-deficient mutant was treated with plasma mutagenesis to obtain NXdP, an engineering strain. Ultimately, the yield of purified sanxan produced by strain NXdP increased from 14.88 ± 0.83 g/L to 21.20 ± 0.38 g/L in a 5 L bioreactor, while the cell dry weight (CDW) was decreased from 9.61 ± 0.14 g/L to 3.12 ± 0.15 g/L. The total precipitable material (crude sanxan) produced from NXdP showed higher zero-shear viscosity, light transmittance, and greater gel strength than that from NX02 due to the enhancement of its purity. The engineering strategies explored here are useful for engineering cell factories to produce other valuable metabolites.

100 Deals associated with Recombinant Porcine factor VIII ( Beijing Neoletix Biological )

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hemophilia	Preclinical	CN	Beijing Neoletix Biological Technology	-
Hemorrhage	Preclinical	CN	Beijing Neoletix Biological Technology	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Recombinant Porcine factor VIII ( Beijing Neoletix Biological )

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation